Piramal Gets Delhi HC Relief, Decades-Old Spurious Tixylix Cough Syrup Case Quashed

However, Piramal challenged the proceedings, arguing that the Ghaziabad laboratory lacked the capacity to perform the required tests as per the D&C Act and Rules. The company pointed to a subsequent test on the same batch conducted at the Government Analyst’s Laboratory in Vadodara, Gujarat, which found the product to be of standard quality.

Also Read: Piramal Slapped Rs 1502 Cr GST Demand Over Pharma Business Sale

Highlighting the contradictory government lab reports, the court in its August 28 judgment observed that “if two views are possible on the same evidence, the one favoring the accused must prevail.”

The High Court also flagged a procedural lapse: the Drug Inspector had failed to send both the Ghaziabad test report and the sealed sample to the manufacturer, as mandated under the D&C Act.

Concluding that no prima facie case had been made out, the bench discharged Piramal and its officials from the long-pending litigation, bringing closure to a case that had lingered for more than 20 years, the Hindu reported.